Metoprolol - IntelGenx

Drug Profile

Metoprolol - IntelGenx

Alternative Names: INT-0001; INT-0001/2004

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator IntelGenx Corp.
  • Class Antihypertensives; Antimigraines; Class II antiarrhythmics; Heart failure therapies; Ischaemic heart disorder therapies; Propanolamines
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hypertension

Highest Development Phases

  • Suspended Heart failure; Hypertension

Most Recent Events

  • 30 Mar 2016 Suspended - Phase-II for Heart failure in Canada (PO)
  • 30 Mar 2016 Suspended - Phase-II for Hypertension in Canada (PO)
  • 23 Mar 2016 Metoprolol - IntelGenx is available for licensing as of 23 Mar 2016. http://www.intelgenx.com/partnering/default.aspx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top